These revealed that CAAs are common in cancers, yet they are tumour type-specific, and CAA burden is associated with TP53 mutations, cell proliferation, cell cycle gene expression and low levels of tumour-infiltrating immune cells. The gene discussed is TP53; the disease is cancer.